Yuichiro Hayashi Selected Research

Intra-Arterial Infusions

10/2019	Proton Beam Therapy for Locally Recurrent Parotid Gland Cancer.
3/2019	Thermochemoradiotherapy Using Superselective Intra-arterial Infusion for Patients With Oral Cancer With Cervical Lymph Node Metastases.
1/2019	Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy.
7/2018	Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial.
1/2018	Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases.
10/2017	Re-irradiation using proton beam therapy combined with weekly intra-arterial chemotherapy for recurrent oral cancer.
3/2016	Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III-IVB tongue cancer.
1/2016	Preliminary results of proton beam therapy combined with weekly cisplatin intra-arterial infusion via a superficial temporal artery for treatment of maxillary sinus carcinoma.
1/2016	Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuichiro Hayashi Research Topics

Disease

24	Neoplasms (Cancer) 01/2021 - 07/2011
15	Lung Neoplasms (Lung Cancer) 01/2021 - 04/2011
9	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2012
7	Adenocarcinoma of Lung 02/2020 - 04/2012
6	Carcinoma (Carcinomatosis) 02/2021 - 08/2008
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 11/2012
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019 - 08/2013
4	Stomach Neoplasms (Stomach Cancer) 01/2021 - 05/2016
4	Squamous Cell Carcinoma of Head and Neck 03/2019 - 01/2016
4	Tongue Neoplasms (Tongue Neoplasm) 07/2018 - 03/2016
4	Adenocarcinoma 11/2017 - 08/2013
3	Mouth Neoplasms (Oral Cancer) 03/2019 - 10/2017
3	Lymphatic Metastasis 03/2019 - 04/2015
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021 - 09/2015
2	Inflammation (Inflammations) 01/2021 - 01/2016
2	Hyperthermia 03/2019 - 01/2019
2	Carcinogenesis 01/2015 - 10/2014
2	Leukocytosis (Pleocytosis) 02/2012 - 02/2012
1	Abdominal Aortic Aneurysm 01/2022
1	Hypersensitivity (Allergy) 01/2022
1	Ulcerative Colitis 02/2021
1	Colitis 02/2021
1	Diabetes Complications 01/2021
1	Multiple Myeloma 07/2020
1	Dehydration (Water Stress) 03/2020
1	Margins of Excision 03/2020
1	Thrombosis (Thrombus) 01/2020
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2020
1	Intracranial Aneurysm (Cerebral Aneurysm) 01/2020
1	Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer) 01/2020
1	Parotid Neoplasms 10/2019
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 03/2019
1	Gastroesophageal Reflux (GERD) 01/2018
1	Infections 01/2018
1	Pneumonia (Pneumonitis) 01/2018
1	Carcinoid Tumor (Carcinoid) 05/2016
1	Cushing Syndrome 05/2016
1	Idiopathic Pulmonary Fibrosis 04/2016
1	Seizures (Absence Seizure) 03/2016

Drug/Important Bio-Agent (IBA)

6	Cisplatin (Platino)FDA LinkGeneric 10/2019 - 01/2016
4	Indicators and Reagents (Reagents)IBA 01/2021 - 01/2016
3	Docetaxel (Taxotere)FDA Link 03/2019 - 07/2018
3	ErbB Receptors (EGF Receptor)IBA 01/2017 - 11/2012
3	Biological ProductsIBA 01/2017 - 01/2014
2	Immune Checkpoint InhibitorsIBA 02/2021 - 01/2021
2	LigandsIBA 01/2021 - 11/2017
2	NivolumabIBA 01/2021 - 01/2020
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 07/2020 - 02/2012
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2012
2	Tyrosine Kinase InhibitorsIBA 01/2017 - 10/2014
2	Biomarkers (Surrogate Marker)IBA 08/2013 - 11/2012
1	Contrast MediaIBA 01/2022
1	sotorasibIBA 01/2021
1	RamucirumabIBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2021
1	AZD4547IBA 01/2021
1	Hemoglobins (Hemoglobin)IBA 01/2021
1	AcidsIBA 03/2020
1	pentaerythritolIBA 03/2020
1	AntibodiesIBA 02/2020
1	InterferonsIBA 02/2020
1	Transforming Growth Factors (Transforming Growth Factor)IBA 02/2020
1	B7-H1 AntigenIBA 02/2020
1	Fibrinogen (Factor I)FDA Link 01/2020
1	osimertinibIBA 01/2020
1	Retinaldehyde (Retinal)IBA 01/2020
1	Cetuximab (Erbitux)FDA Link 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2018
1	Granzymes (Granzyme)IBA 11/2017
1	ChemokinesIBA 11/2017
1	Interferon-gamma (Interferon, gamma)IBA 11/2017
1	AfatinibIBA 01/2017
1	ceritinibIBA 01/2017
1	Adrenocorticotropic Hormone (ACTH)FDA Link 05/2016
1	sodium thiosulfate FDA Link 03/2016
1	CytokinesIBA 03/2016
1	alectinibIBA 01/2016
1	AlbuminsIBA 01/2016
1	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 01/2016
1	C-Reactive ProteinIBA 01/2016

Therapy/Procedure

12	Drug Therapy (Chemotherapy) 01/2021 - 01/2013
9	Therapeutics 01/2021 - 12/2012
9	Intra-Arterial Infusions 10/2019 - 01/2016
8	Chemoradiotherapy 11/2020 - 03/2016
8	Proton Therapy 10/2019 - 12/2015
8	Radiotherapy 01/2019 - 07/2011
4	Gastrectomy 08/2020 - 05/2016
2	Surgical Navigation Systems 03/2020 - 05/2016
2	Segmental Mastectomy (Lumpectomy) 01/2013 - 04/2012
1	Molecular Targeted Therapy 01/2021
1	General Anesthesia 01/2021
1	Glycemic Control 01/2021
1	Ligation 03/2019
1	Aftercare (After-Treatment) 10/2017
1	Re-Irradiation 10/2017
1	Prostheses and Implants (Prosthesis) 06/2016
1	Computer-Assisted Surgery (Image Guided Surgery) 05/2016
1	Electrodes (Electrode) 03/2016